Ken Griffin Entera Bio Ltd. Transaction History

Citadel Advisors LLC

  • $505 Billion
  • Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Entera Bio Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 2,600 shares of ENTX stock, worth $5,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,600
Holding current value
$5,875
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$1.48 - $2.14 $30,418 - $43,983
20,553 New
20,553 $39,000
Q1 2024

May 15, 2024
BUY
$0.64 - $1.72 $8,001 - $21,503
12,502 New
12,502 $20,000
Q3 2023

Nov 14, 2023
BUY
$0.6 - $0.88 $9,201 - $13,495
15,336 Added 47925.0%
15,368 $11,000
Q2 2023

Aug 14, 2023
BUY
$0.68 - $1.01 $21 - $32
32 New
32 $0
Q4 2022

Feb 14, 2023
BUY
$0.5 - $1.05 $15,232 - $31,988
30,465 New
30,465 $22,000
Q2 2022

Aug 15, 2022
SELL
$1.33 - $2.95 $3,192 - $7,080
-2,400 Reduced 15.94%
12,657 $17,000
Q1 2022

May 16, 2022
SELL
$1.91 - $3.23 $23,934 - $40,475
-12,531 Reduced 45.42%
15,057 $43,000
Q4 2021

Feb 14, 2022
SELL
$2.82 - $4.79 $34,601 - $58,773
-12,270 Reduced 30.78%
27,588 $77,000
Q3 2021

Nov 15, 2021
SELL
$4.43 - $6.29 $120,992 - $171,792
-27,312 Reduced 40.66%
39,858 $188,000
Q2 2021

Aug 16, 2021
BUY
$2.92 - $6.5 $196,136 - $436,605
67,170 New
67,170 $401,000
Q4 2020

Feb 16, 2021
SELL
$1.03 - $1.24 $22,680 - $27,304
-22,020 Closed
0 $0
Q3 2020

Nov 16, 2020
BUY
$1.05 - $2.2 $23,121 - $48,444
22,020 New
22,020 $28,000

Others Institutions Holding ENTX

# of Institutions
21
Shares Held
5.34M
Call Options Held
2.6K
Put Options Held
100
View Full List

About Entera Bio Ltd.

ENTX Quotes by TradingView
  • Ticker ENTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,809,900
  • Market Cap $65.1M
  • Description
  • Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed ...
More about ENTX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email